Lv632
3170 积分 2021-04-01 加入
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
6天前
已完结
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
12天前
已完结
Safety and Efficacy of Anti–IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis
15天前
已完结
Guidelines for Reporting Outcomes in Trial Reports
19天前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
22天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
22天前
已完结
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
28天前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
1个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1个月前
已完结
射血分数保留的心力衰竭诊断与治疗中国专家共识 2023
1年前
已采纳
皖公网安备34019202002308
